Company intelligence / Profile preview

Sanomics

Sha Tin, Hong Kong

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Sanomics offers commercial genomic and liquid biopsy diagnostics for cancer and is pursuing discovery-stage drug programs targeting CXCR4 for inflammatory bowel disease

Therapeutic areas: OncologyGastroenterology
Modalities: Small moleculeMolecular diagnosticsGenomic diagnosticsLiquid biopsyTissue-based assay
Industry: Biotech

Partnerships

ACT GenomicsArbele (HKSTP partnership in precision oncology diagnostic development)

Beyond the preview

Go deeper on Sanomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sanomics.

Explore the full profile